Q3 EPS Estimate for Assembly Biosciences Raised by Analyst

Posted by Stanley Muller on Aug 20th, 2026

Assembly Biosciences, Inc. (NASDAQ:ASMB – Free Report) – Investment analysts at HC Wainwright upped their Q3 2026 EPS estimates for Assembly Biosciences in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.44) for the quarter, up from their previous estimate of ($0.69). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $1.90 per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q4 2026 earnings at $3.19 EPS, FY2026 earnings at $2.28 EPS, Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at ($0.86) EPS, Q3 2027 earnings at ($0.87) EPS and FY2027 earnings at ($0.02) EPS.

A number of other research analysts have also issued reports on ASMB. Mizuho set a $45.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a report on Monday, June 15th. Guggenheim restated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a report on Thursday, May 28th. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Check Out Our Latest Report on ASMB

Assembly Biosciences Trading Up 5.3%

Assembly Biosciences stock opened at $33.84 on Thursday. The firm has a market capitalization of $688.98 million, a P/E ratio of 33.18 and a beta of 1.10. Assembly Biosciences has a twelve month low of $20.23 and a twelve month high of $39.71. The stock’s fifty day simple moving average is $26.66 and its 200-day simple moving average is $27.50.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The firm had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million.

Hedge Funds Weigh In On Assembly Biosciences

Several large investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,319 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Assembly Biosciences during the 4th quarter worth about $147,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at about $228,000. Virtus Investment Advisers LLC purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at about $251,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth about $353,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Trending Headlines about Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and sharply improved its Q1 2027 forecast to a profit of $0.02 per share from a $0.16 loss. These revisions suggest stronger expected near-term earnings. HC Wainwright Reiterates Buy Rating for Assembly Biosciences
Positive Sentiment: The firm also narrowed its projected losses for Q3 2026 to $0.44 per share from $0.69, Q2 2027 to $0.86 from $1.18, and Q3 2027 to $0.87 from $1.18. Its FY2027 loss estimate improved significantly to $0.02 per share from $0.77, indicating expectations for Assembly Biosciences to approach breakeven.
Positive Sentiment: Analysts maintained the $50 price objective and Buy rating, while a separate report said Assembly Biosciences carries a Moderate Buy consensus rating. The positive ratings and higher earnings forecasts are likely the main reasons investor sentiment has improved. Assembly Biosciences Receives Consensus Rating of Moderate Buy
Neutral Sentiment: Not all revisions were positive: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69 and trimmed its Q4 2027 estimate to $1.63 from $1.66. However, the firm still expects FY2026 profitability and retained its Buy recommendation.

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.